Objectives. To evaluate efficacy of short term intranasal corticosteroid (mometasone furoate) treatment in pediatric sleepdisordered breathing (SDB) patients. Methods. A prospective, observational study was done. A total of 41 children (2-11 years old) were enrolled into this study. All patients received 4-weeks course of mometasone furoate 100 μg/day treatment. They were evaluated at pretreatment and immediately after treatment with obstructive sleep apnea (OSA)-18 quality of life survey and lateral neck X-ray. Also, the assessment of each patients included history, skin prick test or CAP test, and sinus radiography. We compared the OSA-18 survey score and adenoidal-nasopharyngeal (AN) ratio between before and after treatment. Results. Total OSA-18 score and AN ratio decreased significantly after treatment regardless of allergy, sinusitis, and obesity (P=0.003, P=0.006). There was no complication after treatment of mometasone furoate. Conclusion. Pediatric SDB patients with adenoid hypertrophy could be effectively treated with 4-weeks course of mometasone furoate. Allergy, obesity, and sinusitis did not affect on the result of treatment. © 2011 by Korean Society of Otorhinolaryngology-Head and Neck Surgery.
CITATION STYLE
Jung, Y. G., Kim, H. Y., Min, J. Y., Dhong, H. J., & Chung, S. K. (2011). Role of intranasal topical steroid in pediatric sleep disordered breathing and influence of allergy, sinusitis, and obesity on treatment outcome. Clinical and Experimental Otorhinolaryngology, 4(1), 27–32. https://doi.org/10.3342/ceo.2011.4.1.27
Mendeley helps you to discover research relevant for your work.